Showing 1211-1220 of 9359 results for "".
- Industry Vet James P. Hartman Named New Chief Commercial Officer at Alastinhttps://practicaldermatology.com/news/industry-vet-james-p-hartman-named-new-chief-commercial-officer-at-alastin/2457772/James P. Hartman is the new Chief Commercial Officer of Alastin Skincare, Inc.— effective May 14, 2018. Mr. Hartman recently served as Vice President & General Manager at Solta Medical, a division of Valeant Pharmaceuticals. Prior to Solta, he was at Merz Aesthetics where he was the Vice President…
- ALASTIN Adds to Board of Directorshttps://practicaldermatology.com/news/alastin-adds-to-board-of-directors/2457837/Ann Rhoads and Elisabeth Sandoval are now members of ALASTIN Skincare, Inc’s Board of Directors. Ms. Rhoads is a healthcare finance executive with more than 25 years of experience which includes roles as Chief Financial Officer of two companies, raising over $400M through public and private offeri…
- FDA Greenlights NDA for New Impetigo Treatmenthttps://practicaldermatology.com/news/fda-greenlights-nda-for-new-impetigo-treatment/2458449/The U.S. Food and Drug Administration (FDA) has accepted Medimetriks Pharmaceuticals, Inc.'s New Drug Application (NDA) for their novel impetigo treatment, ozenoxacin cream, 1%. Ozenoxacin cream is a non-fluorinated quinolone. The Prescription Drug User Fee Act (PDUFA) date for the completion of …
- Valeant Terminates European Licensing Rights for Brodalumabhttps://practicaldermatology.com/news/valeant-terminates-european-licensing-rights-for-brodalumab/2458512/Valeant Pharmaceuticals International, Inc.'s affiliate and AstraZeneca have amended Valeant's license for brodalumab, an IL-17 receptor monoclonal antibody under regulatory review for patients with moderate-to-severe plaque psoriasis, to terminate Valeant's right to develop and commercialize broda…
- Alphaeon to Acquire Clarion Medical Technologieshttps://practicaldermatology.com/news/20140909-alphaeon_to_acquire_clarion_medical_technologies/2459125/Alphaeon Corporation, a subsidiary of Strathspey Crown Holdings LLC, and Clarion Medical Technologies Inc. entered into a definitive agreement for Alphaeon to acquire all of the outstanding shares and assets of Clarion, a provider of medical and aesthetic equipment and consumables in Canada, for an…
- Caliber Imaging & Diagnostics Appoints Robert P. Fischmann VP of Operationshttps://practicaldermatology.com/news/20131125-caliber_imaging__diagnostics_appoints_robert_p_fischmann_vp_of_operations/2459406/Caliber Imaging & Diagnostics, formerly Lucid, Inc., has appointed Robert P. Fischmann to the role of Vice President of Operations, a newly created position. Mr. Fischmann's responsibilities at Caliber I.D. will include managing all of the Company's production control, production process developme…
- The American Academy of Dermatology Elects New Officers and Board Membershttps://practicaldermatology.com/news/the-american-academy-of-dermatology-elects-new-officers-and-board-members/2458941/The American Academy of Dermatology (AAD) announced the results of its annual election. The newly elected officers and board members will lead the AAD, which represents more than 19,000 physicians. These officers and board members also will hold the same positions for the American Academy of Dermat…
- ASDS Honors Legacy of Dr. Fredric Brandthttps://practicaldermatology.com/news/asds-honors-legacy-of-dr-fredric-brandt/2458958/The American Society for Dermatologic Surgery is paying tribute to the late cosmetic dermatologist Fredric S. Brandt, MD by setting up two memorial funds in his honor. Dr. Brandt, an ASDS member since 1982, died earlier this month at age 65 at his Florida home. The ASDS said the funds are designed…
- EMA Accepts LEO Pharma’s MAA for Delgocitinib Cream in Chronic Hand Eczemahttps://practicaldermatology.com/news/ema-accepts-leo-pharmas-maa-for-delgocitinib-cream-in-chronic-hand-eczema/2461942/The European Medicines Agency (EMA) has validated LEO Pharma’s marketing authorization application for delgocitinib cream, an investigational product and topical pan-Janus kinase (JAK) inhibitor for the treatment of adult patients with moderate to severe chronic hand eczema (CHE). The acceptance …
- August Is Psoriasis Action Month: Experts Offer Treatment Tipshttps://practicaldermatology.com/news/august-is-psoriasis-action-month-experts-offer-treatment-tips/2461915/August is Psoriasis Action Month and serves as a good time to make sure that your patients are being adequately treated with available therapies, psoriasis experts tell DermWire. Psoriasis is common, affecting 7.5 million in the US, one-third of whom are candidates for either systemic/biologic th…